ME Therapeutics Holdings Inc.
METX
CNSX
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 743.80K | 777.90K | 865.80K | 921.30K | 898.50K |
| Depreciation & Amortization | 7.60K | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 964.00K | 1.01M | 1.06M | 1.05M | 967.40K |
| Operating Income | -964.00K | -1.01M | -1.06M | -1.05M | -967.40K |
| Income Before Tax | -917.80K | -950.00K | -1.01M | -5.11M | -5.03M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.92 | -0.95 | -1.01 | -5.11 | -5.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -917.80K | -950.00K | -1.01M | -5.11M | -5.03M |
| EBIT | -964.00K | -1.01M | -1.06M | -1.05M | -967.40K |
| EBITDA | -963.10K | -1.01M | -1.06M | -1.05M | -967.40K |
| EPS Basic | -0.04 | -0.04 | -0.05 | -0.32 | -0.32 |
| Normalized Basic EPS | -0.02 | -0.02 | 0.14 | -0.03 | -0.03 |
| EPS Diluted | -0.04 | -0.04 | -0.06 | -0.33 | -0.33 |
| Normalized Diluted EPS | -0.02 | -0.02 | 0.14 | -0.03 | -0.03 |
| Average Basic Shares Outstanding | 99.06M | 97.43M | 87.86M | 78.40M | 60.90M |
| Average Diluted Shares Outstanding | 99.06M | 97.43M | 87.86M | 78.40M | 60.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
